During the past decade, Minnesota Epilepsy Group, P.A. conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 9 clinical trials were completed, i.e. on average, 56.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Minnesota Epilepsy Group, P.A." #1 sponsor was "Marinus Pharmaceuticals" with 4 trials, followed by "Novartis Pharmaceuticals" with 4 trials sponsored, "Lundbeck LLC" with 3 trials sponsored, "Takeda" with 3 trials sponsored and "Eisai Inc." with 3 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Minnesota Epilepsy Group, P.A." #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "The Epilepsy Study Consortium" with 2 trials as a collaborator, "Bausch Health Americas, Inc." with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "Novotech Health Holdings Pte. Ltd." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Minnesota Epilepsy Group, P.A." are "Epilepsy" (8 trials), "Seizures" (4 trials), "Tuberous Sclerosis Complex" (3 trials), "Dravet Syndrome" (2 trials) and "Dravet Syndrome (DS)" (2 trials). Many other conditions were trialed in "Minnesota Epilepsy Group, P.A." in a lesser frequency.

Most popular intervention types in "Minnesota Epilepsy Group, P.A." are "Drug" (26 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Ganaxolone" (3 trials), "Soticlestat" (3 trials), "Clobazam High Dose" (2 trials) and "Clobazam Low Dose" (2 trials). Other intervention names were less common.

The vast majority of trials in "Minnesota Epilepsy Group, P.A." are 30 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Minnesota Epilepsy Group, P.A.". undefined are not yet recruiting, 2 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Minnesota Epilepsy Group, P.A., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Minnesota Epilepsy Group, P.A., 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".